Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bausch & Lomb

This article was originally published in The Gray Sheet

Executive Summary

Delaware lower court injunction against U.S. manufacture and sale of PureVision continuous-wear contact lenses is amended to allow distribution of the lenses to participants in the firm's 5,000-patient post-approval study. FDA requires a post-approval study for all manufacturers of 30-day continuous-wear contact lenses; B&L's study commenced in March 2002. The firm reports that it has completed the transfer of PureVision manufacturing from its Rochester, N.Y. plant to Ireland. B&L filed an appeal with the D.C. federal appeals court in June 2002...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017680

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel